A unique model
IRIC, located in the heart of the Université de Montréal campus, operates according to a unique model in Canada that combines, under one roof, fundamental research activities, a university-level training program and a research maturation team. These generate discoveries that advance knowledge or that can quickly translate into new therapeutic solutions.
Recent tweets
@IRIC_umontreal
mai 12, 2022
📣 L’IRIC se réjouit de l’annonce de @MinFitzgibbon @economie_quebec, quant au dévoilement de la Stratégie québécoi… https://t.co/l8yOdWAqf3
Retweeted
:
@JCellBiol
mai 6, 2022
RT @JCellBiol: Interphase microtubule disassembly is a signaling cue that drives cell rounding at mitotic entry, say @kevin_leguay, @Carren…
Retweeted
:
@IRSC_CIHR
mai 5, 2022
RT @IRSC_CIHR: Félicitations à la Dre Geneviève Deblois @IRIC_umontreal qui a reçu un Prix de début de carrière en recherche sur le cancer…
-
![]()
News SQSV 2022-2025: Encouraging news for the industry!
IRIC is pleased with the announcement of the Quebec Minister of Economy and Innovation, Mr. Pierre Fitzgibbon, regarding the unveiling of the Quebec Life Sciences Strategy 2022-2025 during the renowned event Effervescence. Under the theme “Using our ingenuity to advance health”, the strategy, updated in the context of COVID-19, proposes concrete and innovative actions to promote this key industry of the Quebec economy and encourage its growth.
-
![]()
News Les Rendez-vous Audace 2022: Dr. Eralda Kina answers your questions
Les Rendez-vous Audace of the IRIC, held on April 27, brought together André Robitaille and three inspiring speakers around the theme “A world in transformation, a next generation in action”. Eralda Kina, oncologist and doctoral student at IRIC in the laboratory of Claude Perreault, discussed her experience as a clinician and the great hopes she has in immunology and cancer research. Dr. Kina generously agreed to answer the questions received from the public during the broadcast of Les Rendez-vous Audace.
-
![]()
News Geneviève Deblois Honoured by the Canadian Institutes of Health Research
Geneviève Deblois, Principal Investigator at IRIC and Assistant Professor at the Faculty of Pharmacy of the Université de Montréal, is the recipient of the Early Career Investigator in Cancer Award 2022. This award, presented by the Institute of Cancer Research of the Canadian Institutes of Health Research (CIHR), recognizes excellence in research conducted in Canada. It is awarded to the top-ranked new investigators in the CIHR fall competition, Project Scheme.
-
![]()
News Identification of a new key role for interphase microtubules at mitosis entry
At the beginning of cell division, cells round-up through different mechanisms, notably the reorganization of their cortex. Among the proteins involved in this cell morphogenesis, there is the family of ERM proteins (ezrin, radixin and moesin). The team of Professor Sébastien Carréno, Director of the Cellular Mechanisms of Morphogenesis during Mitosis and Cell Motility Research Unit, wanted to identify the molecular cue activating these proteins at mitotic entry. Their work has shed light on a novel mechanism involving interphase microtubules in the regulation of cell rounding at mitotic onset. The project, led by PhD student Kévin Leguay, is the subject of a publication in the Journal of Cell Biology.
-
![]()
News Publication of two studies characterizing the selectivity of G protein-coupled receptors’ coupling
Two-thirds of human hormones and one-third of clinical drugs target and activates the G protein-coupled receptors. For a given receptor, different ligands can selectively engage different subsets of signaling pathways. Mapping the effectors that can be engaged by a given receptor is essential for understanding physiological processes as well as for designing safer drugs. The team of Professor Michel Bouvier, Director of the Molecular Pharmacology Research Unit and Chief Executive Officer of IRIC, worked on characterizing the coupling selectivity of GPCRs.
Upcoming events
Latest publications
See all publications-
mai 1, 2022 The timing of Start is determined primarily by increased synthesis of the Cln3 activator rather than dilution of the Whi5 inhibitor.
Litsios A, Goswami P, Terpstra HM, Coffin C, Vuillemenot LA, Rovetta M, Ghazal G, Guerra P, Buczak K, Schmidt A, Tollis S, Tyers M, Royer CA, Milias-Argeitis A, Heinemann M
Mol Biol Cell 2022-05-01 ;33( 5 ):rp2. - See all publications